Status:
COMPLETED
An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This non-interventional prospective study will assess the safety of Herceptin SC (subcutaneous administration) as used in routine clinical practice. Patients with HER2-positive early breast cancer, na...
Eligibility Criteria
Inclusion
- Aged \>/= 18 years
- Patients with HER2-positive early breast cancer who according to national guidelines are eligible for neoadjuvant or adjuvant HER2+ treatment
- Patients for whom the investigator has decided to start a treatment with Herceptin SC
- Trastuzumab treatment naive or non-naive (previously intravenous treatment)
- Informed consent
Exclusion
- Patients previously treated with Herceptin SC treatment
Key Trial Info
Start Date :
January 14 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 10 2016
Estimated Enrollment :
510 Patients enrolled
Trial Details
Trial ID
NCT02286362
Start Date
January 14 2015
End Date
November 10 2016
Last Update
September 27 2017
Active Locations (97)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique Du Docteur Calabet; Cromg
Agen, France, 47000
2
C H Du Pays D'Aix En Provence; Hopital De Jour
Aix-en-Provence, France, 13616
3
Ch Du Pays D Aix; Maternite Gynecologie
Aix-en-Provence, France, 13616
4
Poly Parc Rambot La Provencale; Chimiotherapie Ambulatoire
Aix-en-Provence, France, 13617